Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Dec 2024 02:36 PM
RNS
Holding(s) in Company
04 Dec 2024 07:00 AM
RNS
Appointment of Company Secretary
09 Sep 2024 07:01 AM
RNS
Extension of Warrants in Incanthera to 31 Mar 2025
09 Sep 2024 07:00 AM
RNS
Half-year Report
06 Aug 2024 01:41 PM
RNS
Holding(s) in Company
28 Jun 2024 12:17 PM
RNS
Result of AGM
06 Jun 2024 04:20 PM
RNS
Holding(s) in Company
06 Jun 2024 04:20 PM
RNS
Holding(s) in Company
05 Jun 2024 02:01 PM
RNS
Notice of AGM & Annual Report & Accounts
05 Jun 2024 07:00 AM
RNS
Final Results
03 Jun 2024 10:09 AM
RNS
Realisation-c£1.5m on sale of shares in Incanthera
03 May 2024 07:00 AM
RNS
Holding(s) in Company
24 Apr 2024 07:12 AM
RNS
IMMUPHARMA AT BIO-EQUITY 2024 12-14 May
19 Apr 2024 07:00 AM
RNS
Grant of Share Options
02 Apr 2024 07:03 AM
RNS
New intellectual property strategy initiated
25 Mar 2024 07:25 AM
RNS
Incanthera provides Comm'l Update/Revenue F'casts
19 Mar 2024 07:00 AM
RNS
Grant of Share Options
14 Mar 2024 07:00 AM
RNS
IMMUPHARMA AT BIO-EUROPE SPRING 2024
06 Mar 2024 07:00 AM
RNS
Financial, Business and Portfolio Develop't Update
28 Dec 2023 01:35 PM
RNS
Holding(s) in Company
19 Dec 2023 02:50 PM
RNS
Holding(s) in Company
19 Dec 2023 07:00 AM
RNS
Simbec-Orion appointed as CRO
18 Dec 2023 07:15 AM
RNS
Incanthera - Comm'l Skincare Deal/£1M Fundraise
13 Sep 2023 03:47 PM
RNS
Holding(s) in Company
07 Sep 2023 07:00 AM
RNS
Result of Retail Offer and Director Shareholding
06 Sep 2023 01:53 PM
RNS
Holding(s) in Company
31 Aug 2023 07:02 AM
RNS
WRAP Retail Offer for up to £0.5m
31 Aug 2023 07:01 AM
RNS
Subscription to raise £1.35m; Sharing Agr, RPT
31 Aug 2023 07:00 AM
RNS
Interim results
21 Aug 2023 07:00 AM
RNS
Extension of warrants in Incanthera plc
11 Aug 2023 12:04 PM
RNS
Directorate Change
30 Jun 2023 01:12 PM
RNS
Result of AGM
19 Jun 2023 07:00 AM
RNS
Lupuzor Update
06 Jun 2023 07:00 AM
RNS
IMM RNS Posting of RA and Notice of AGM 30 June 23
18 May 2023 07:00 AM
RNS
Positive Pre-IND meeting with FDA
11 May 2023 07:00 AM
RNS
Final Results
10 May 2023 01:56 PM
RNS
Holding(s) in Company
19 Apr 2023 07:00 AM
RNS
Lupozor Update - FDA confirms Type-C meeting date
12 Apr 2023 07:00 AM
RNS
CIDP P140 Clinical Program Update
27 Mar 2023 07:00 AM
RNS
LupuzorT Update
09 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
06 Mar 2023 07:00 AM
RNS
Collaboration with Orano on ImmuPharma Peptide
06 Feb 2023 07:00 AM
RNS
LupuzorT Update
27 Jan 2023 04:25 PM
RNS
TR-1: Notification of major holdings
04 Jan 2023 05:26 PM
RNS
TR-1: Notification of major holdings
04 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
04 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
03 Jan 2023 04:58 PM
RNS
TR-1: Notification of major holdings
22 Dec 2022 07:55 AM
RNS
Grant of Options
22 Dec 2022 07:00 AM
RNS
End of Year Update

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100